Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect ® MM Registry (2010–2016)

Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2018.04.007
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Progress in the Front-Line Treatment of Multiple Myeloma

European Oncology and Haematology
OncologyHematology
2010English

Bortezomib for the Treatment of Multiple Myeloma Patients

Health Technology Assessment
MedicineHealth Policy
2009English

Durable Remission With Salvage Second Autotransplants in Patients With Multiple Myeloma

Cancer
Cancer ResearchOncology
2011English

Clinical Implications of Cytogenetic Heterogeneity in Multiple Myeloma Patients With TP53 Deletion

Modern Pathology
Forensic MedicinePathology
2017English

The Danish National Multiple Myeloma Registry

Clinical Epidemiology
Epidemiology
2016English

Pcn115 a Cross-Country Comparison of Second-Line Multiple Myeloma Treatments

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Treatment Patterns and Outcomes in Elderly Patients With Multiple Myeloma,

Blood
BiochemistryImmunologyCell BiologyHematology
2011English

Psy222 - Health Related Quality of Life (Hrqol) in Multiple Myeloma (Mm) Patients in Bulgaria

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Successful Treatment of Extramedullary Tumors With Low-Dose Thalidomide in Patients With Multiple Myeloma

Internal Medicine
Internal MedicineMedicine
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy